Eli Lilly CEO calls Amodei’s disease-cure timeline unlikely
Original title: Eli Lilly CEO pushes back on Dario Amodei's ludicrous medical claims
Dave Ricks said biology is still largely unmapped and human proof, not model forecasts, is the long pole in drug development.
Anthropic CEO Dario Amodei said cancer, Alzheimer’s, heart disease and mental illness could be relics of the past in less than a decade, in remarks tied to an IPO video. Eli Lilly chairman and CEO Dave Ricks replied that such an outcome would be amazing but is not likely, and that progress from AI in medicine will probably be steady and incremental. Gary Marcus and several researchers argued clinical timelines make that prediction unrealistic.
Unconfirmed: The disease-cure timeline is Amodei’s prediction; researchers and Ricks dispute it, and the clinical-timeline figures come from social-media comments.
- Amodei’s quoted horizon is less than a decade for those diseases.
- Ricks said randomized human proof remains the constraint.
- One cited figure: mean time from first-in-human to FDA approval was 14 years for 20 recent drugs.
- Marcus frames the claims as overpromising comparable to Theranos rhetoric.
From the original article
6 min read at garymarcus.substack.com
Moments after I posted my essay on why I couldn’t touch Anthropic’s IPO with a ten-foot pole, Anthropic’s CEO gave me (and everyone else) a reason to run away as fast as possible: a video tied to the IPO launch in which he made a bunch of overpromise about medicine that would have made Elizabeth Holmes blush.
By Noaidi · garymarcus.substack.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.